Ross Harrison, MD MPH

#gynonc at @OHSUKnight. Views are mine; no COIs.

[Ross Harrison, MD MPH @RossFH]

Multicenter retrospective study of patients with early #cervicalcancer (n=675) finds assessment of tumor size by preoperative exam and/or MRI have good concordance (>80%) with surgical pathology measurements. #gyncsm @P@Pan_Teresa_MD @pedroramirezMD @IJGConline https://t.co/afmZwfp0s4

[Ross Harrison, MD MPH @RossFH]

Randomized trial of patients with high-risk #endometrialcancer (n=1095) did not find improvement in disease-free survival from adding #pembrolizumab to postoperative adjuvant treatment (HR 1.02, 95% CI 0.79-1.32, p=.57). Pembrolizumab was associated with better survival (HR 0.31, 95% CI 0.14-0.69) for patients with MMR deficient tumors (n=281). #gyncsm @Annals_Oncology https://t.co/HwY5YuIQZv

[Moffitt Cancer Center @MoffittNews]

Today at the @RivkinCenter AACR Ovarian Cancer Research Symposium Moffitt’s Karen Lu, MD (@karenluMD) co-chairs the Prevention, Early Detection, & Interception session. Check out her video to learn more!

⏰: 9/20 -4:50 p.m. PDT
📍: Washington Ballroom
Learn more ➡️ https://t.co/xd2CucnCxp

[Nicole D. Fleming MD @nicoleflemingmd]

Excited to represent @SGO_org @GYNCancer as Social Media Ambassador for our 2025 Annual #SGOMtg! ⏰ Abstract submission deadline is approaching quickly Sept 27th! We will Multiply Your Impact through our exciting program and social media!💥Join us in Seattle! #AM25IMPACT #gyncsm

[Ross Harrison, MD MPH @RossFH]

Surgical video reviewing uterine transposition, patient selection, & postoperative management.👏👏👏 #crcsm #ayacsm #gynonc #gyncsm @leitaomd @JennyMueller_ @MSKCancerCenter @AnnSurgOncol https://t.co/8Uuuynvw8P

[National Cancer Institute @theNCI]

People with advanced #EndometrialCancer now have new FDA-approved treatment options: pembrolizumab and durvalumab, paired with chemotherapy, for tumors with a genetic change called mismatch repair deficiency. https://t.co/NnZoeLR5oO

[Ross Harrison, MD MPH @RossFH]

@leitaomd Do you think we should have different staging systems for different histologies? Or that staging should exclusively reflect extent of disease from an anatomic standpoint?

[Ross Harrison, MD MPH @RossFH]

@leitaomd During our tumor board discussions we typically mention both.

[Ross Harrison, MD MPH @RossFH]

Nice presentation of FIGO 2023 #endometrialcancer staging. From a review in @NatRevClinOncol. @jahow514 https://t.co/Hi9wV454Hi

[NCI Cancer Stats @NCICancerStats]

Rates of new #UterineCancer cases increased by 0.7% each year from 2012 to 2021. The death rate from uterine cancer increased by 1.5% each year from 2013 to 2022. Visit our Cancer Stat Facts sheet to learn more: https://t.co/V9433PjGI5 #GynCSM

[OHSU Knight Cancer Institute @OHSUKnight]

From medical enigma to a roadmap for recovery, one @OHSUNews patient's life-altering journey through a rare skin, musculature condition and stage 3 cancer.

This is Kathy's remarkable story: https://t.co/WLxMEBNxuS

[IJGC @IJGConline]

#Small bite fascial closure reduces #incisional hernia rates in #GynOncology patients by @uppals @astraubhar

📄 https://t.co/R19J37GDwk

@umichMedicine @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4

[Ross Harrison, MD MPH @RossFH]

Dr. Frumovitz has made an incredible impact in #gynonc, both as a gifted educator & researcher. Consider a gift to honor his contributions to our field & support his research in the treatment of rare #gyn cancers. https://t.co/p3ztPBWdf7 @Frumovitz @MDAndersonNews @SGO_org @IGCSociety @IJGConline @gynoncjnls #gyncsm

[NCI Cancer Stats @NCICancerStats]

The rate of new #OvarianCancer cases fell by 2.7% each year from 2012 – 2021 and the death rate fell by 2.4% each year from 2013 – 2022. Visit our Cancer Stat Facts sheet to learn more: https://t.co/HWrp6HOzTG #GynCSM #WorldOvarianCancerDay

[Ziad Obermeyer @oziadias]

Ever wonder why your insurer charges a copay for statins (and other high-value meds)?

Don’t they want to prevent heart attacks, strokes, etc?

Copays never made sense to me.

In this new paper in @QJEHarvard, we show copays kill. 🧵

https://t.co/3PHeckLiZM

[Ross Harrison, MD MPH @RossFH]

Adding cisplatin to radiation doesn't improve progression-free survival for localized recurrent #endometrialcancer but does increase treatment-related toxicity. Radiation remains standard of care. https://t.co/nrcx1wXOXf @JCO_ASCO @AnnKloppMD @dsmgyo #gyncsm #gynonc

[Shitanshu Uppal @uppals]

Dear members of @sgo, a question came up during our journal club and I cannot find the answer. Can someone please help?
Why did investigators in the RUBY trial pick 3 years of Dostarlimab maintenance? Is there a biologic explanation? @matthewapowell #endometrialcancer